Dr. Paul MacLeman, CEO of Genetic Technologies said, This is an important further step in Genetic Technologies ™ move into advanced cancer management. As previously announced, we are seeking to leverage in-house developed tests through partnerships with third party developers of novel tests. This agreement, which follows a similar distribution arrangement with Rosetta Genomics Inc. and Trimgen Inc., will assist us to expand our growing portfolio of genetic tools that will enable oncologists to more effectively manage patient diagnosis and therapy, improving treatment outcomes. Genetic Technologies is very excited to announce its relationship with Response Genetics, an acknowledged leader in the area of cancer diagnostic test development.

ResponseDX?„? genetic tests are available in the United States through direct sales and through NeoGenomics Laboratories, the exclusive national clinical reference laboratory authorized to offer Response Genetics ™ proprietary tests. All tests are performed through Response Genetics ™ CLIA-certified laboratory.